Napigen Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Series A
  • (Cancelled)

  • Investors
  • 13

Napigen General Information

Description

Operator of a biotechnology company intended to address novel genome engineering of various organisms, such as plants, microbes, and animals. The company's technology targets two special cellular components known as organelles that harbor their DNA, named mitochondria and chloroplasts, which are important to create energy for cells to grow, enabling clients to harness the potential of organelles to make our society a convenient place to live.

Contact Information

Website
www.napigen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 200 Powder Mill Road
  • DISI-E500
  • Wilmington, DE 19803
  • United States
+1 (302)
Primary Industry
Biotechnology
Other Industries
Other Agriculture
Drug Discovery
Corporate Office
  • 200 Powder Mill Road
  • DISI-E500
  • Wilmington, DE 19803
  • United States
+1 (302)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Napigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series A) 11-Mar-2024 Cancelled Generating Revenue
12. Accelerator/Incubator Completed Generating Revenue
11. Later Stage VC 12-Jul-2022 Completed Generating Revenue
10. Grant 01-Jun-2022 Completed Generating Revenue
9. Later Stage VC 08-Nov-2021 Completed Generating Revenue
8. Grant 31-Dec-2020 Completed Generating Revenue
7. Grant 01-Sep-2020 Completed Generating Revenue
6. Early Stage VC 12-Nov-2019 Completed Generating Revenue
5. Early Stage VC 25-Oct-2019 $1M $1.6M Completed Generating Revenue
4. Grant 18-Sep-2019 $100K $600K Completed Generating Revenue
To view Napigen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Napigen Patents

Napigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260286374-A1 Methods and compositions for genome editing in plants Pending 13-Jan-2025
WO-2026151941-A2 Methods and compositions for genome editing in plants Pending 13-Jan-2025
WO-2026151941-A3 Methods and compositions for genome editing in plants Pending 13-Jan-2025
AU-2024230907-A1 Herbicide-resistant genes for mitochondrial transformation Pending 09-Mar-2023
EP-4677099-A2 Herbicide-resistant genes for mitochondrial transformation Pending 09-Mar-2023 C12N15/8275
To view Napigen’s complete patent history, request access »

Napigen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Napigen Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
RA Capital Management Asset Manager Minority
The Grantham Foundation Limited Partner Minority
Thiel Foundation Not-For-Profit Venture Capital Minority
United States Department of Agriculture Government
Angel (individual) Minority
You’re viewing 5 of 13 investors. Get the full list »

Napigen FAQs

  • When was Napigen founded?

    Napigen was founded in 2016.

  • Where is Napigen headquartered?

    Napigen is headquartered in Wilmington, DE.

  • What is the size of Napigen?

    Napigen has 15 total employees.

  • What industry is Napigen in?

    Napigen’s primary industry is Biotechnology.

  • Is Napigen a private or public company?

    Napigen is a Private company.

  • What is Napigen’s current revenue?

    The current revenue for Napigen is .

  • How much funding has Napigen raised over time?

    Napigen has raised $9.6M.

  • Who are Napigen’s investors?

    RA Capital Management, The Grantham Foundation, Thiel Foundation, United States Department of Agriculture, and are 5 of 13 investors who have invested in Napigen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process